Merited Wealth’s Gilead Sciences GILD Stock Holding History

Merited Wealth’s Portfolio GILD Stock Details GILD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-70	Closed	-$8.59K	–	161
2025 Q4	$8.59K	Buy	+70	New	+$8.51K	0.01%	203

Other funds holding GILD

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Merited Wealth's GILD Position: Q1 2026 in Review

Merited Wealth sold out of Gilead Sciences (GILD) in Q1 2026, closing a stake of 70 shares — an estimated $8.59K sold.

Merited Wealth first reported a position in GILD in Q4 2025 and held it in 1 quarter. The position peaked at $8.59K in Q4 2025. 2,320 funds tracked by Wall St. Rank hold GILD as of Q1 2026.

Merited Wealth reported no remaining Gilead Sciences position as of Q1 2026 after selling out during the quarter.
Merited Wealth sold 70 Gilead Sciences shares in Q1 2026, an estimated $8.59K.
Merited Wealth first reported a position in Gilead Sciences in Q4 2025 and held it in 1 quarter.
Merited Wealth's Gilead Sciences position peaked at $8.59K in Q4 2025.
2,320 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2026.

Based on Merited Wealth's 13F filing for Q1 2026, filed 24 Apr 2026.